57852-57-0

• 常用中文名：盐酸依达比星
• 常用英文名：Idarubicin (hydrochloride)
• CAS号：57852-57-0
• 分子式：C₂₆H₂₈ClNO₉
• 分子量：533.955
• 相关类别： 原料药 抗肿瘤药 抗生素类抗肿瘤药
• 发布时间：2018-08-28 13:22:09
• 更新时间：2026-06-30 19:40:12
• Idarubicin hydrochloride是一种蒽环类抗白血病药物。 它抑制 拓扑异构酶II,干扰DNA复制和RNA转录。

名称

• 中文名: 盐酸依达比星
• 英文名: Idarubicin HCl
• 中文别名: Idubicin HCl 10mM * 1mL in DMSO试剂; (7S,9S)-9-乙酰基-7-((2R,4S,5S,6S)-4-氨基-5-羟基-6-甲基四氢-2H-吡喃-2-基)氧基)-6,9,11-三羟基-7,8,9,10-四氢并四苯-5,12-二酮盐酸盐; 去甲氧基柔红霉素盐酸盐; 依达吡星; Idubicin HCl :盐酸伊达比星; 盐酸依达吡星; 盐酸伊达比星; 盐酸依达比星Idubicin Hydrochloride; 盐酸伊达比星,去甲氧基柔红霉素盐酸盐,盐酸去甲氧基柔红霉素; 盐酸依达比星 (去甲氧基柔红霉素盐酸盐、盐酸伊达比星); 伊达比星盐酸盐; 盐酸伊达柔比星; 盐酸伊达比星 Idubicin hydrochloride; 肌肽锌(聚普瑞锌); 盐酸伊达比星盐; 盐酸伊达比星,10 MM DMSO 溶液; 盐酸依达比星 标准品; 盐酸依达比星杂质; Idubicin HCl 5mg试剂; 依达比星盐酸; 盐酸雷洛昔芬; 盐酸伊达比星,盐酸依达比星; 盐酸去甲氧基柔红霉素; DNA拓扑异构酶II抑制剂
• 英文别名: Ida Bixing ketone; (1S,3S)-3-Acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-tetracenyl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside hydrochloride (1:1); Edabixing hydrochloride impurity; (1S,3S)-3-Acetyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside, hydrochloride; Idubicin hcl; Daunomycin, 4-demethoxy-, hydrochloride; 4-demethoxydaunomycin hydrochloride; 5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, hydrochloride, (7S,9S); (7S-cis)-9-Acetyl-7-((3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxynaphthacene-5,12-dione hydrochloride; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione hydrochloride; 4-demethoxydaunorubicinhydrochloride; (7S-cis)-9-Acetyl-7-((3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,9,11-trihydroxynaphthacene-5,12-dione Hydrochloride; demethoxydaunorubicin hydrochloride; 5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, hydrochloride, (7S-cis); 4-demethoxydaunorubicin (NSC256439， 4-DMDR) HCl; (7S,9S)-9-acetyl-7-((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydro-2H-pyran-2-yloxy)-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride; 4-DMDR) HCl; Idubicin HCL for; Idubicin HCI; 4-DMD HCl; Idubicin hydrochloride salt; Idarubicin hcl USP/EP; IdarubicinHCl; 4-demethoxydaunorubicin (NSC256439; IDUBICIN HYDROCHLORIDE; 5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S,9S)-, hydrochloride (1:1); Idubicin hydrochloride,Idubicin HCl; Idamycin; Idubicin HCl API; 5,12-naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S,9S)-, hydrochloride (1:1); 5,12-Naphthacenedione,9-acetyl-7-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-,hydrochloride (1:1), (7S,9S); Idarubicin HCL for research; 4-Demethoxydaunorubicin hydrochloride; 5,12-naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-, (7S,9S)-, hydrochloride; (7S,9S)-9-acetyl-7-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-Methyloxan-2-yl]oxy}-6,9,11-trihydroxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione; Idubicin Hydrochloride (50 mg); Idubicin hydrochloride, 10 mM in DMSO; (1S,3S)-3-Acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside hydrochloride (1:1); Idubicin hydrochloride: (7S,9S)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione Hydrochloride; DMDR, Idamycin, IMI-30, (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; (7S,9S); Idubicin Hydrochloride(NSC-256439, IdaMycin); Idabicin hydrochloride; 4-demethoxy-daunomycihydrochloride; Idubicin hydrochloride //BP; (7S-cis)-9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxynaphthacene-5,12-dione hydrochloride; Idubicin hydrochloride, >=; (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside hydrochloride (1:1); Zavedos; (7S,9S)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione Hydrochloride; 5,12-Naphthacenedione, 9-acetyl-7-[(3-amino-2,3,6-trideoxy- .alpha.-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro- 6,9,11-trihydroxy-, hydrochloride, (7S-cis); (7s-cis)-9-acetyl-7-[(3-amino-2,3,6-trideoxy-α-l-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; (7S,9S)-9-acetyl-7-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride; IDARUBICIN HYDROCHLORIDE; (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside hydrochloride

物化性质

• 沸点: 725.4ºC at 760 mmHg
• 熔点: 183-185ºC
• 分子式: C₂₆H₂₈ClNO₉
• 分子量: 533.955
• 闪点: 392.5ºC
• 精确质量: 533.145264
• PSA: 176.61000
• LogP: 2.52260
• 外观性状: 粉末
• 储存条件: -20℃

生物活性

• 描述: Idarubicin hydrochloride是一种蒽环类抗白血病药物。 它抑制 拓扑异构酶II,干扰DNA复制和RNA转录。
• 相关类别:
  信号通路 >> 自噬 >> 自噬
  信号通路 >> 细胞周期/DNA损伤 >> 拓扑异构酶
  研究领域 >> 癌症
• 靶点:

  Topoisomerase II

• 体外研究: 伊达比星的IC50在MCF-7单层上为3.3±0.4 ng/mL,在多细胞球体中为7.9±1.1 ng/mL [1]。在各种体外系统中,Idarubicin比柔红霉素或多柔比星显示出更大的细胞毒性。这归因于伊达比星更好地诱导拓扑异构酶II介导的DNA断裂的形成[2]。伊达比星的活性分别比阿霉素和表柔比星高约57.5倍和25倍[3]。 Idarubicin产生浓度依赖性细胞生长减少,IC50值约为0.01μM。 Idarubicin产生浓度依赖性的DNA合成抑制[4]。
• 细胞实验: 将盐酸伊达比星的储备溶液溶解在蒸馏水（1mg / mL）中。将MCF-7单层以0.01,0.1,1,10,100和1000ng / mL暴露于伊达比星或其代谢物伊达比星，持续24小时。多细胞球体暴露于相同范围的伊达比星和伊达比星浓度单层（0.01-1000 ng / mL）24小时，并且在单独的实验中，药物浓度为100 ng / mL，持续6,12,24和48小时。通过用血细胞计数器计数活细胞来确定细胞增殖的抑制。结果表示为细胞存活与对照培养物的百分比[1]。
• 参考文献:

  [1]. Orlandi P, et al. Idarubicin and idarubicinol effects on breast cancer multicellular spheroids. J Chemother. 2005 Dec;17(6):663-7.

  [2]. Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet. 1993 Apr;24(4):275-88.

  [3]. Siegsmund MJ, et al. Enhanced in vitro cytotoxicity of idarubicin compared to epirubicin and doxorubicin in rat prostate carcinoma cells. Eur Urol. 1997;31(3):365-70.

  [4]. Gewirtz DA, et al. Induction of DNA damage, inhibition of DNA synthesis and suppression of c-myc expression by the anthracycline analog, idarubicin (4-demethoxy-daunorubicin) in the MCF-7 breast tumor cell line. Cancer Chemother Pharmacol. 1998;41(5):361-

毒性和生态

CHEMICAL IDENTIFICATION RTECS NUMBER : HB7877000 CHEMICAL NAME : Daunomycin, 4-demethoxy-, hydrochloride CAS REGISTRY NUMBER : 57852-57-0 LAST UPDATED : 199612 DATA ITEMS CITED : 8 MOLECULAR FORMULA : C26-H27-N-O9.Cl-H MOLECULAR WEIGHT : 534.00 WISWESSER LINE NOTATION : L E6 C666 BV MVT&&&J DQ FQ HV1 HQ KQ RQ HEALTH HAZARD DATA ACUTE TOXICITY DATA TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 5430 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 26,364,1995 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 2930 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 26,364,1995 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - rat DOSE/DURATION : 3080 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 26,364,1995 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 13980 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 26,364,1995 TYPE OF TEST : LDLo - Lowest published lethal dose ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 700 ug/kg TOXIC EFFECTS : Tumorigenic - active as anti-cancer agent REFERENCE : CTRRDO Cancer Treatment Reports. (Washington, DC) V.60-71, 1976-87. For publisher information, see JNCIEQ. Volume(issue)/page/year: 60,829,1976 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Subcutaneous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 4690 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 26,364,1995 TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 4100 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 26,364,1995 TYPE OF TEST : LD - Lethal dose ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED : Mammal - dog DOSE/DURATION : >500 ug/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 26,364,1995

安全

• 符号: GHS06, GHS08
• 信号词: Danger
• 危害声明: H300-H351-H360
• 警示性声明: P201-P264-P281-P301 + P310-P308 + P313
• 个人防护装备: Eyeshields;Faceshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
• 危害码 (欧洲): T+:Verytoxic;
• 风险声明 (欧洲): R60;R61;R28;R40
• 安全声明 (欧洲): S53-S45
• 危险品运输编码: UN 2811
• RTECS号: HB7877000

上下游产品

上游产品  6
60660-74-4 23541-50-6 68594-06-9 26388-52-3
60660-75-5 52583-22-9
下游产品  1
64363-63-9